The Diagnosis Sales Enablement Refuses to Make

It is Tuesday morning, twelve days from the end of Q1 2026, and the VP of Sales is staring at her Salesforce board.

Seven yellow bars. Four of them stuck. One cold coffee.

The four stuck bars have been at "demo scheduled" for nine weeks. Her CRO walks past her office and says, "back half is going to come together," without breaking stride. She nods.

She does not believe him.

She just got off a call with the Highspot rep who sold her the platform in 2024. He is now pitching her a "buyer indecision module" built on top of JOLT. Her enablement budget for the year is $380K. Of that, $240K is already committed to a Force Management rollout that kicks off in April. She knows she is going to buy the indecision module too. She also knows it will not work.

She has not said the second part out loud to anyone.

A Note Before the Indictment

I spent seventeen years writing the content the sellers in this story used. Case studies, white papers, the cost-of-inaction one-pagers the rep emailed at hour 47 of a stalled cycle. I was the person whose work was supposed to carry buyers from marketing engagement to a closed deal, and for most of those years I believed the gap was a content problem. It was not. I was inside the misdiagnosis for over a decade before I could name it. I once spent a week building a fourteen-page cost-of-inaction PDF for a $2.4M Salesforce implementation deal. The buyer's champion thanked me for the asset. The deal died at no-decision sixty-one days later because the CFO had never seen the PDF and the procurement lead had three objections nobody had surfaced. I am not writing this from the outside.

The Quarter Q1 2026 Made Undeniable

The pipeline looked healthy in October. By February it was dead at week six.

That is not a story about her company. That is the story of every enterprise SaaS earnings call this quarter.

Workday named it. On their Q4 FY26 call on February 24, president Rob Enslin said plainly: "Some net new large enterprise deals are taking longer to close, particularly in Fed, SLED, and healthcare." Monday named it. CFO Eliran Glazer told analysts on February 9 that "the 2027 number is currently off the table," and pinned it to buyer behavior. GitLab named it by slipping deals into next quarter and refusing to call the slip a one-time event. And Asana named it the most directly: on the March 2 call, CEO Dan Rogers told analysts, "There is a structural shift in how customers are discovering and evaluating and experiencing software."

Four earnings calls. Four different framings. One pattern.

Underneath the four calls is a number you already know if you have read any buying-research in the last eighteen months. Forrester puts the average enterprise buying group at 22 stakeholders. Of those groups, 74% report unhealthy internal conflict during the decision. That is not a sales-cycle problem. That is the buyer's organization failing to align with itself, in a meeting your rep was not invited to, three weeks before the demo your CRM is still tracking at 70%.

Your enablement spend is aimed at her rep. The blockage sits inside the buyer's conference room.

The Category That Diagnosed Itself in 2022

In 2022, the Challenger team published JOLT. The research was clean and the diagnosis was correct: 40-60% of qualified pipeline ends in no decision, 87% of buyers report high indecision during the cycle, and 56% of qualified deals close to "no decision, let's revisit next quarter" (Dixon & McKenna, 2022).

The diagnosis was not "your reps need to close harder." The diagnosis was that the buyer is paralyzed. Omission bias. Outcome uncertainty. Information overload. The decision is not failing because the seller is weak. It is failing because the buyer cannot bring themselves to commit to a future they cannot prove.

That research should have changed how revenue leaders spent enablement money. It did not.

What happened instead is that the same category that conducted the research turned around and packaged the diagnosis as a sales-rep training module. The JOLT framework got repackaged three ways: as a training curriculum on top of existing methodologies, as a discovery-question overlay reps could run during demos, and as a "deconstructing indecision" workshop that revenue leaders could expense. The research said the problem lives in the buyer's head. The product said the fix lives in the rep's mouth.

You see where this is going.

The Cure That Sells the Diagnosis Back to You

The category named the problem in 2022 and has been selling the wrong fix ever since.

One of those four stuck deals has a champion who has not forwarded a single internal artifact in six weeks. That deal is not slow. It is not a deal.

That is the pipeline you are looking at on a Tuesday morning. None of those four conditions improves because your rep got better at handling objections. None of them improves because your rep ran a tighter discovery. They improve when the buyer does work the seller cannot do for them, and that work happens in rooms the seller is not in.

Five Vendors, One Conflict of Interest

The Force Management rollout starts in April. The Highspot renewal sits in the Q3 budget. The Corporate Visions messaging refresh is scheduled for Q3. Richardson is in the pipeline as a "future investment." Challenger has a new module on, you guessed it, buyer indecision.

Five vendors. One playbook.

Here is Highspot, in their own words on their "Activate Buyer Urgency" blog post: "When reps empower buyers with new and relevant information, sellers can reduce buyer indecision and expedite sales cycles. In fact, more than half (58%) of CROs believe that ensuring reps can effectively engage buyers is what good looks like for sales enablement."

Read that twice. The buyer's cognitive state is named in the first sentence, buyer indecision, full stop. By the second sentence, it has been recast as a content-delivery problem solvable by rep behavior. The diagnosis lives on the buyer's side of the table. The product acts on the seller's. The pivot happens inside a single paragraph, in the vendor's own marketing copy.

The other four are running the same play. Richardson sells you a Connected Selling curriculum that trains your reps to read the buying committee. Corporate Visions sells you messaging frameworks that train your reps to articulate cost-of-inaction. Force Management sells you Command of the Message, training your reps to compete for mindshare inside a deal. Challenger sells you the original methodology plus an indecision overlay, training your reps to take control of the buyer's evaluation.

The diagnosis in every one of them lives on the buyer's side of the table. The product in every one of them acts on the seller's.

Three signs you are looking at the same conflict of interest. The vendor names buyer indecision in their marketing copy. The vendor sells rep training as the fix. The vendor renews you on the same diagnosis a year later and reports that "skill gaps" explain why close rates did not move.

The vendor naming the disease is the vendor selling the wrong cure.

That is not a training gap. That is a diagnosis gap.

Score the Buyer, Not the Deal

So what do you do on Tuesday morning, twelve days before quarter close, with seven yellow bars and four of them stuck?

You do not throw out the pipeline review. You change what the review measures.

Stage is what the seller did. Readiness is what the buyer decided.

Right now, every column in your CRM tracks rep activity. Demo scheduled. Proposal sent. Verbal received. Each one is a verb the seller performed. None of them is a verb the buyer performed. That is why your forecast slips: you are forecasting on a column that does not reflect what the buyer is actually doing.

Replace the stage column with three buyer-readiness columns:

1. Conviction. Has the buyer named, in their own words, the cost of doing nothing? Not in your discovery notes. In a written artifact they produced. A board memo, a slide they showed their CFO, an internal Slack thread their champion forwarded. If the seller is the only person who has named the cost of inaction, conviction does not exist. The deal is at zero, no matter what stage your CRM says.

2. Alignment. Has the buying committee surfaced and resolved internal disagreement, or are they still in the polite phase where everyone says "this is interesting" and nobody says "here is what I would have to give up"? Forrester's 74% conflict number is the ceiling. If your rep cannot name the three loudest objections inside the buyer's organization, alignment does not exist.

3. Authority. Does your champion have signing authority, or is your champion a translator who has to convince the actual decision maker in a room your rep will never enter? If the answer is translator, you are running a two-stage sale and the second stage is invisible to you.

Now ask the buyer-evidence questions in your next pipeline review. Ask what the buyer wrote down. Ask what the buyer changed in their own process. Ask what the buyer told their boss. Ask what the buyer would lose if they paused.

Open Monday's pipeline review. Strike the stage column. Add the three readiness columns. Score the buyer, not the deal. Forecast only what the buyer has done.

Audit the Enablement Spend

The next move is the budget. Most of the line items act on the wrong side of the table.

This is not an argument that rep training is wrong. Rep training is right when the problem is rep skill. The argument is that the budget is unbalanced because the diagnosis was unbalanced. You bought five seller-side products to fix a two-sided problem.

Sort every line item in your enablement budget into one of three buckets:

1. Seller-side activity. Methodology rollouts, discovery training, messaging frameworks, sales coaching platforms, conversation intelligence. These act on what your rep does in a meeting. They are useful when the bottleneck is the rep. They are useless when the bottleneck is the buyer.

2. Buyer-side diagnosis. Tools and frameworks that score the buyer's readiness, surface the buying committee's internal alignment, or generate artifacts the buyer takes back to their own organization. ROI tools the buyer types into. Cost-of-inaction frameworks the buyer signs off on. Stakeholder maps your champion can use to identify dissent.

3. Neither. CRM hygiene, dashboarding, content libraries that nobody reads. These are infrastructure, not enablement. Treat them as IT spend.

Run that sort across your $380K. The first time you do it, you will find that 80-90% of the spend lives in bucket one. That is the misallocation in plain numbers.

Stop Buying the Diagnosis Back

Now the renewal conversation. The Highspot indecision module sits in next quarter. Force Management kicks off in April. Three vendors have proposals on your desk for "buyer-centric" trainings.

Before you sign any of them, ask three questions. Does this product act on the seller side or the buyer side of the table? Does the vendor have evidence that close rates improve when buyers go through the experience, not just when reps complete the training? When this contract renews in twelve months, what artifact will my buyer produce that they did not produce before?

If the vendor cannot answer all three, you are renewing on a category mismatch. The contract will close. The close rate will not move. Twelve months from now, the vendor's QBR deck will explain that "skill adoption was uneven" and recommend a deeper rollout.

A vendor that diagnoses correctly and prescribes wrongly is not a partner. It is a category mismatch on a renewal cycle, and the renewal is the line item to cut.

The Same Tuesday, the Same Seven Yellow Bars

It is still Tuesday morning. Same coffee. Same yellow bars. Same CRO walking past with the same line.

This time she does not nod.

She opens a new tab. She pulls up the four nine-week deals. She writes a single column next to each one: "what has the buyer done in the last 30 days to make a decision possible." Three of the cells are empty. The fourth says "asked for a reference call, never scheduled it."

She closes the laptop. She knows what the back half looks like now.

It looks like four deals that were never deals.

And every one of them was on the board nine weeks ago, marked at 70%, in the column she was forecasting against.